1. Introduction {#sec1}
===============

45S5 Bioglass^®^ with a composition of 46.1SiO~2~-24.4Na~2~O-26.9CaO-2.6P~2~O~5~ in mol% was discovered by Prof. Larry Hench in 1969 \[[@bib1],[@bib2]\]. Various clinical products were developed based on 45S5 Bioglass^®^, such as orthopedics products for trauma, arthroplasty and spine fusion, cranial-facial products for cranioplasty, general oral/dental defect and periodontal repair, and dental-maxillofacial-ENT products (e.g., toothpaste, pulp capping, sinus obliteration, repair of orbital floor fracture) \[[@bib3]\]. After the discovery of 45S5, many new bioactive glass compositions have been developed, since the glass matrix can accommodate various elements while maintaining the glass character and properties \[[@bib4],[@bib5]\]. This composition flexibility enables the possibility to introduce additional functional elements that can potentially benefits to human body \[[@bib6]\] such as enhancement of osteo-growth by Sr^2+^ \[[@bib7], [@bib8], [@bib9]\], angiogenesis by Cu^2+^ \[[@bib10], [@bib11], [@bib12]\], antibacterial by Ag^+^ \[[@bib13]\]. Recently, B~2~O~3~ containing bioactive glasses have drawn attention due to its potential effects and consequential biomedical applications, such as osteogenesis \[[@bib14], [@bib15], [@bib16], [@bib17], [@bib18]\], angiogenesis \[[@bib19]\], soft tissue repair \[[@bib20]\], supporting tissue infiltration \[[@bib21]\], controllable glass dissolution \[[@bib21],[@bib22]\], improving coating adhesion \[[@bib23],[@bib24]\], widening the processing window \[[@bib25]\] and improving mechanical properties \[[@bib26]\]. Accurate evaluation of the compositional effect, in particular the amount of B~2~O~3~, on the *in vitro* and *in vivo* bioactivity becomes critical while designing bioactive glass compositions for these applications.

Bioactive material is defined as a material that stimulates beneficial responses from the living tissue, organisms or cells, by inducing the formation of hydroxyl apatite (HAp) through which the material bonds to the host tissue \[[@bib4]\]. Inorganic glasses in certain compositions such as 45S5 or other bioactive glasses, following the initial dissolution, illicit formation of HAp on the glass surface. The ability to form HAp in biological environment thus presents a means of evaluating the bioactivity of materials. There are generally two ways to evaluate bioactivity: in vitro and *in vivo* methods. An *in vitro* method evaluates bioactivity by testing the material in controlled environment outside living organism, such as by immersing materials in solutions such as simulated body fluid (SBF) or cell cultures. *In vitro* method is in general more economical and easier to implement as compared to an *in vivo* method which requires living organisms such as animal models. Nevertheless, it was found that bioactivity evaluated *in vitro* is generally agreeable with *in vivo* bioactivity with a few exceptions \[[@bib27],[@bib28]\]. However, many challenges exist in study dissolution and bioactivity of glass materials *in vitro* \[[@bib29]\], where testing conditions (e.g., glass mass \[[@bib30]\] or glass surface area \[[@bib31]\] to solution volume ratio, particle size \[[@bib32]\], SBF preparation \[[@bib27]\], medium pH \[[@bib33]\], ion concentration \[[@bib34]\], buffer type \[[@bib35]\] and solution replenishment frequency \[[@bib36]\]) directly affect the final results and interpretation of the glass bioactivity. For instance, mixed results were found in terms of bioactivity of boron-containing silicate glasses. Several studies showed that replacing SiO~2~ with B~2~O~3~ produced a more rapid conversion of the glass to HAp \[[@bib21],[@bib22],[@bib32]\], while some studies have also shown that the addition of boron impeded the HAp formation *in vitro* \[[@bib31],[@bib37], [@bib38], [@bib39], [@bib40], [@bib41]\]. Various testing conditions can be one of the main reasons that caused these non-conclusive results from these studies.

In this work, we adopted a unified evaluation protocol proposed by Macon et al. \[[@bib29]\] for bioactivity evaluation of glasses. The main objective is to investigate solution effects on HAp formation of boron-containing glasses *in vitro* by using both SBF and K~2~HPO~4~ with three different treatments. The rest of paper is arranged as following: methodology of glass synthesis procedure, bioactivity evaluation details and characterizations will be reported first. Then the results on characterizations of original glass samples, FTIR spectra of samples after different solution treatments and HAp morphology observed by SEM are presented. This is followed by discussions and conclusions.

2. Methodology {#sec2}
==============

2.1. Glass synthesis procedures {#sec2.1}
-------------------------------

Compositions of the glasses studied in this paper are shown in [Table 1](#tbl1){ref-type="table"}. SiO~2~ was gradually (10, 20 and 30%) replaced by B~2~O~3~. The glasses were prepared by thoroughly mixing analytical grade H~3~BO~3~, NH~4~H~2~PO~4~, SiO~2~, NaCO~3~ and CaCO~3~ chemicals before melting in an Al~2~O~3~ crucible at 1300 °C for 2 h in an electrical furnace (Deltech Furnaces). Molten glasses were poured onto a stainless plate and cooled to room temperature.Table 1Composition (mol%) of the glasses studied.Table 1SampleComposition (mol%)B~2~O~3~SiO~2~Na~2~OCaOP~2~O~5~0B046.124.426.92.65B4.641.524.426.92.69B9.236.924.426.92.614B13.832.324.426.92.6

Powder glass samples were prepared by manually crushing the bulk glass of each composition, grinding with an alumina mortar and pestle, and sieving to 32--45 μm with stainless steel sieves. Glass powders were cleaned in deionized (DI) water and ethanol two times each in an ultrasonic cleanser, respectively. Cleaned glass powders were oven-dried (90 °C) overnight and pending for in vitro tests.

2.2. Bioactivity evaluations {#sec2.2}
----------------------------

0.02 mol/L K~2~HPO~4~ solution was prepared by dissolving reagent grade K~2~HPO~4~∙3H~2~O in DI water, where the starting pH was 9.10 at room temperature, following studies on other boron-containing glasses \[[@bib42], [@bib43], [@bib44]\]. pH measurements were performed on a bench-top pH/mV meter (Sper Scientific) with an accuracy of ±0.02 pH. Simulated body fluids (SBFs) were prepared according to a study of Kokubo and Takadama \[[@bib27]\] by mixing reagent grade chemicals in the following order: NaCl (8.035 g), NaHCO~3~ (0.355 g), KCl (0.225 g), K~2~HPO~4~∙3H~2~O (0.231 g), MgCl~2~∙6H~2~O (0.311 g), 1 mol/L HCl (39 mL), CaCl~2~ (0.292 g) and Na~2~SO~4~ (0.072 g) in DI water (700 mL) with a plastic beaker at 37 °C. After the chemicals completely dissolved, DI water was added up to 900 mL in total, and the pH of the solution was 1.5 ± 0.1 at the time. The fluid was buffered to a pH value of 7.40 at 36 ± 0.5 °C by slowly adding tris (trihydroxymethyl)-aminomethane (total 6.118 g) and drops of 1 mol/L HCl alternately in order to maintain a fluctuation of pH values between 7.40 and 7.45. After dissolving all tris(trihydroxymethyl)-aminomethane, the solution was filled with DI water up to 1 L at room temperature.

Powder samples were used for in vitro tests, following a unified evaluation proposed by Macon et al. \[[@bib29]\]: each 75 ± 0.5 mg glass powder was put in a polypropylene tube (Corning Inc.) with a 50 mL solution at 37 ± 0.2 °C up to 10 days. The tubes were agitated at an interval time throughout the in vitro tests to prevent glass powders from sticking together. Three different solution treatments were conducted on each glass composition: 1) no refreshment or adjustment of solutions was performed (referred as "still treatment"); 2) solutions were adjusted with HCl drops every 24 h to maintain a pH value of 7.4 (referred at "adjusted treatment"); 3) solutions were refreshed every 24 h (referred as "refreshed treatment"). Glass powders were obtained at different time intervals, washed in ethanol and oven-dried (90 °C) overnight. [Fig. 1](#fig1){ref-type="fig"} shows an outline of the experimental details.Fig. 1Outline of the experimental details.Fig. 1

2.3. Glass characterizations {#sec2.3}
----------------------------

Glass powders were characterized with high-resolution X-ray diffraction (XRD) on a Rigaku Ultima III with a scanning speed of 3°/min and a step of 0.03°/point. XRD pattern analysis was performed with JADE 9 software package.

Fourier transform infrared spectrometer (FTIR) equipped with an attenuated total reflection (ATR) sampling technique was conducted with a Nicolet 6700 spectrometer (Thermo Electron) at room temperature. A diamond substrate was used for the ATR sampling. A total of 32 scans for background and per sample were used with a resolution of 2 cm^−1^. A commercial HAp powder (calcium phosphate tribasic) obtained from Fisher Scientific was taken as a reference material.

Scanning electron microscopy (SEM) was conducted on a FEI Quanta ESEM to observe surface morphology of SBF treated samples after Au--Pd coating.

3. Results {#sec3}
==========

XRD patterns of the four glass samples obtained from the melt-quench process are shown in [Fig. 2](#fig2){ref-type="fig"}. 14B sample was partially crystallized as shown in [Fig. 2](#fig2){ref-type="fig"}, where ﻿the crystalline phases could be Na~3~Ca~6~(PO~4~)~5~ or hexagonal Na~2~Ca~4~(PO~4~)~2~SiO~4~, as studied previously \[[@bib41]\]. [Fig. 3](#fig3){ref-type="fig"} presents photos of the glass samples. Even though no crystallization peaks were observed from XRD pattern of 9B, there are heterogeneous phases in 9B as visually observed from the sample (shown in [Fig. 3](#fig3){ref-type="fig"} (c)). In our previous studies \[[@bib39],[@bib41]\], it was also observed that addition of boron increases the crystallization tendency of both 45S5 and 55S4.3 bioactive glasses at low SiO~2~/B~2~O~3~ substitution, while no crystallization was found at high substitution levels (\>50%). ﻿It was found that crystallization delayed the initial time of HAp formation on 45S5 but did not inhibit the formation of HAp \[[@bib45]\].Fig. 2XRD patterns of the prepared glass samples.Fig. 2Fig. 3Photos of the prepared glass samples.Fig. 3

[Fig. 4](#fig4){ref-type="fig"} and [Fig. 5](#fig5){ref-type="fig"} show the FTIR spectra of 0B and 5B after SBF immersion with three different solution treatments (still, adjusted and refreshed), along with a FTIR spectrum of a commercial HAp powder for reference. The appearance of a split phosphate P--O bending band (∼560 and 600 cm^−1^), P--O stretching band (∼1015 cm^−1^) and a carbonate band (∼870 cm^−1^) indicates the formation of HAp \[[@bib46]\]. For both 0B and 5B samples, refreshing SBF every 24 h promotes the HAp formation on glass surface, while still and adjusted treatments exhibit slower and similar HAp formation. However, for 9B and 14B samples, no HAp formation was identified by FTIR after SBF treatments for 10 days (shown in [Fig. 6](#fig6){ref-type="fig"} and [Fig. 7](#fig7){ref-type="fig"}).Fig. 4FTIR spectra of ﻿the commercial HAp powder and 0B after SBF immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 4Fig. 5FTIR spectra of ﻿the commercial HAp powder and 5B after SBF immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 5Fig. 6FTIR spectra of ﻿the commercial HAp powder and 9B after SBF immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 6Fig. 7FTIR spectra of ﻿the commercial HAp powder and 14B after SBF immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 7

[Fig. 8](#fig8){ref-type="fig"}, [Fig. 9](#fig9){ref-type="fig"}, [Fig. 10](#fig10){ref-type="fig"} and [Fig. 11](#fig11){ref-type="fig"} show the FTIR spectra of 0B, 5B, 9B and 14B after K~2~HPO~4~ solution immersion with three different solution treatments, respectively. As compared to SBF treatments, HAp formation is much faster in K~2~HPO~4~ solution. Except 14B sample, HAp formation was identified by FTIR after 2 days of immersion for all samples among all the solution treatments. For 14B, HAp formation was not identified after 4 days of immersion for all treatments. Shorter sampling points are needed for K~2~HPO~4~ solution in order to observe difference between glass compositions and solution treatments.Fig. 8FTIR spectra of ﻿the commercial HAp powder and 0B after K~2~HPO~4~ solution immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 8Fig. 9FTIR spectra of ﻿the commercial HAp powder and 5B after K~2~HPO~4~ solution immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 9Fig. 10FTIR spectra of t﻿he commercial HAp powder and 9B after K~2~HPO~4~ solution immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 10Fig. 11FTIR spectra of ﻿the commercial HAp powder and 14B after K~2~HPO~4~ solution immersion with three different solution treatments, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 11

SEM images of 0B after SBF immersion with three different solution treatments are shown in [Fig. 12](#fig12){ref-type="fig"}. Different HAp morphology was observed on glass surface after 7 days of SBF treatments. HAp formed after still treatment ([Fig. 12](#fig12){ref-type="fig"} (a)) has a spherical feature in comparison with the other two treatments, which is consistent with a previous study \[[@bib41]\]. For refreshed treatment, HAp precipitates have a needle-shaped or a flaky feature ([Fig. 12](#fig12){ref-type="fig"} (c)); whereas, HAp formed after pH adjusted treatment (([Fig. 12](#fig12){ref-type="fig"} (b)) are more granular and no other distinguishable features were observed.Fig. 12SEM images of 0B after SBF immersion with three different solution treatments for 7 days, where (a), (b) and (c) is still, adjusted and refreshed, respectively.Fig. 12

4. Discussions {#sec4}
==============

Through this study, we found that different HAp growth behaviors and surface morphology during bioactivity testing when different solutions (SBF versus K~2~HPO~4~ solution) and testing conditions (e.g. static, refreshing, pH control) were used, suggesting complexity of the testing and calling for protocols to evaluate bioactivity of glass and glass-ceramic materials. The results indicate that solution chemistry has a significant effect on glass dissolution and HAp formation, and consequently the bioactivity. These results are in general consistent with those reported in the literature, where various testing conditions such as glass surface area to solution volume ratio \[[@bib31]\], medium pH \[[@bib33]\], ion concentration \[[@bib34]\], buffer type \[[@bib35]\] and solution replenishment frequency \[[@bib36]\] were found to affect the final results and interpretation of the glass bioactivity. The mechanism of HAp formation \[[@bib47],[@bib48]\] generally involves: 1) rapid cation exchange and creating silanol bonds (Si--OH) on the glass surface; 2) breaking Si--O--Si bonds caused by high local pH; 3) condensation of Si--OH groups near the glass surface and repolymerization of the silica-rich layer; 4) migration of Ca^2+^ and PO~4~^3−^ through the silica-rich layer and from the solution, forming a film rich in amorphous CaO--P~2~O~5~ on the silica-rich layer; 5) incorporation of hydroxyls and carbonate from solution and crystallization of the CaO--P~2~O~5~ film to HAp. The Si--OH groups in SiO~2~-rich layer were believed to provide nucleation sites for the apatite formation \[[@bib49],[@bib50]\]; however, some studies have demonstrated that glasses without Si can form HAp in vitro as well \[[@bib21],[@bib22],[@bib31],[@bib32],[@bib51], [@bib52], [@bib53], [@bib54]\]. Solution chemistry can greatly affect the concentration of the ions (particularly Ca^2+^, PO~4~^3−^) critical for HAp formation, dissolution of the glasses, migration of ions from glass and solution, as well as nucleation and crystallization growth of HAp, leading to various results of glass bioactivity evaluations. For example, refreshing the test solutions would provide a constant level of critical ions for HAp formation hence lead to the highest HAp growth rate. This becomes critical when compositions that have low bioactivity are tested. Therefore, choosing the appropriate *in vitro* testing conditions is critical for evaluation and study the bioactivity of glass materials.

Very different conditions were used in the literature for bioactivity testing. For example, tests using the K~2~HPO~4~ solution were usually not buffered while SBF contained TRIS buffer. It was found previously that the TRIS buffer in SBF distorts the assessment of glass-ceramic scaffold bioactivity, where TRIS buffer can increase the dissolving rate (by two times) of the glass and facilitate the HAp formation as compared to SBF solution without TRIS buffer \[[@bib55]\]. As compared to SBF, however, HAp formation was found to be much faster in the K~2~HPO~4~ solution in our study. For instance, HAp formation of 9B was identified by FTIR after immersion in K~2~HPO~4~ solution for 2 days, while no HAp formation was found after SBF immersion for 10 days. This might be caused by the high concentration of HPO~4~^2−^ ions (1.0 mM in SBF \[[@bib27]\] and 20 mM in K~2~HPO~4~ solution) and the high starting pH value (7.4 for SBF and 9.1 for K~2~HPO~4~ solution) of K~2~HPO~4~ solution, resulting a faster glass dissolution and HAp precipitation.

It was found that refreshing SBF every 24 h led to a much quicker HAp formation, while the 0B and 5B samples show the fastest HAp growth. The other two conditions, still or pH adjustment treatments, on the other hand, showed no significant effect on the speed of HAp formation. This indicates that ion concentrations in SBF, which provide source of phosphorus and calcium ions, has a far greater impact on HAp formation than the pH variation. On the other hand, no obvious trend was observed for the three treatments tested using the K~2~HPO~4~ solution. This might be due to the much higher phosphate concentration in K~2~HPO~4~ than SBF, suggesting that shorter sampling intervals are needed for K~2~HPO~4~ solution in order to observe differences between glass compositions and solution treatments.

Different HAp crystal morphologies were observed by SEM imaging for 45S5 samples treated in SBF solution with different conditions. Previously, it was found that the morphology of HAp formed depends on the types of immersion solutions \[[@bib35],[@bib36],[@bib41]\]. In this work, even though the same medium (e.g., SBF) was used, different solution treatments were found to have a noticeable impact on the morphology of HAp formed as well, indicating that ion concentrations in solution and pH can also greatly affect HAp nucleation and formation mechanisms. Surface analyzing tests are desired for better study the effect of solution treatments on the composition of calcium phosphate precipitates (e.g., Ca/P ratio) formed. For example, the increased pH of the SBF during *in vitro* test can affect Ca/P molar ratios and chemical compositions of calcium phosphate precipitates \[[@bib56]\]. HCO~3~^−^ concentration in SBF can affect the thickness of calcium phosphate formed \[[@bib34]\], as well as the heterogeneity and the crystal size of the calcium phosphate precipitates \[[@bib57]\]. Additionally, it was found that chloride ions in TRIS-HCl butter solution were incorporated in the apatite formation during immersion tests, affecting the final composition of precipitates \[[@bib46]\]. Future detailed compositional studies of formed HAp are desired for better understanding the apatite formation mechanism, which can benefit the improvement of *in vitro* bioactivity evaluation of glass materials, as well as designing new functional biomaterials (e.g., apatite formed matches bone or dentin tissue \[[@bib58],[@bib59]\]).

5. Conclusions {#sec5}
==============

The effects of three solution treatment conditions: still, pH adjusted, and refreshed for SBF and K~2~HPO~4~ solutions on HAp formation for *in vitro* bioactivity testing were studied on a series of boron oxide containing 45S5 bioactive glasses. It was found that, in general, substituting SiO~2~ with B~2~O~3~ (up to 30%) in 45S5 delayed the HAp formation in both SBF and K~2~HPO~4~ solutions. Refreshing SBF was found to lead to the fastest HAp formation for low boron-containing glasses, while refreshing solution was found to have no significant differences on the results while using the K~2~HPO~4~ solution. It was also observed that HAp formation is much faster in K~2~HPO~4~ solution as compared to SBF. Additionally, different morphologies of HAp precipitates were observed by SEM on the glass surface of 45S5 after immersion in SBF for 7 days, indicating that ion concentrations and solution pH can affect HAp nucleation and formation mechanisms. These results provide insights on understanding the test conditions on *in vitro* bioactivity testing and how to better evaluate novel bioactive glasses with ever increasing composition domains. Further studies to find out the HAp composition differences would be beneficial to understand the formation mechanisms and how the solution composition affect HAp crystal nucleation and growth.
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